Ritter Pharmaceuticals has enrolled the first patient in its Phase II clinical trial of RP-G28 as a treatment for lactose intolerance.

The randomised, double-blind and placebo-controlled study will evaluate the efficacy, safety and tolerability of RP-G28 in treating the symptoms of the condition.

The study is being conducted in the US states of Hawaii and Texas, and is expected to enrol around 80 patients. Initial study results are expected in the first quarter of 2012.